Curve is transforming the discovery of new therapeutics through direct functional screening of genetically-encoded Microcycle libraries against targets in their native environment. Curve is using its platforms to develop a pipeline of first-in-class therapeutics against a number of challenging cancer targets, including intracellular protein-protein and protein-gene interactions.
Location: United Kingdom, England, Southampton
Total raised: $51.36M
Investors 2
| Date | Name | Website |
| 13.04.2022 | Advent Lif... | adventls.c... |
| - | Epidarex C... | epidarex.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.02.2024 | Series A | $51.36M | - |
Mentions in press and media 1
| Date | Title | Description | Source |
| 27.02.2024 | Curve Therapeutics Raises £40.5M in Series A Funding | Curve Therapeutics, a Southampton, UK-based private biotechnology company, raised $40.5M in Series A... | finsmes.co... |